Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation

International Journal of Cancer

Volumn 86, Issue 4, 2000, Pages 468-473

  Puchner, Maximilian J A ^a,b   Giese, Alf ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Gilead Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; HYPERICIN; STAUROSPORINE; TAMOXIFEN;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; DRUG EFFECT; EXTRACELLULAR MATRIX; GLIOMA CELL; GROWTH CURVE; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; PERYLENE; PROTEIN KINASE C; STAUROSPORINE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0034016221     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000515)86:4<468::AID-IJC4>3.0.CO;2-R     Document Type: Article

References (30)

1. ARITA, N., TANEDA, M. and HAYAKAWA, T., Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta neurochir. (Wien), 126, 84-92 (1994).
2. ARTEAGA, C.L., KOLI, K.M., DUGGER, T.C. and CLARKE, R., Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β. J. nat. Cancer. Inst., 91, 46-53 (1999).
3. BORG, A., BALDETORP, B., FERNO, M., KILLANDER, D., OLSSON, H., RYDEN, S. and SIGURDSSON, H., erbB2 amplification is associated with tamoxifen resistance in steroid-receptor-positive breast cancer. Cancer Lett., 81, 137-144 (1994).
4. CALLAGHAN, R. and HIGGINS, C.F., Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Brit. J. Cancer, 71, 294-299 (1995).
5. CLOUGHESY, T.F., WOODS, R.P., BLACK, K.L., COULDWELL, W.T., LAW, R.E. and HINTON, D.R., Prolonged treatment with biologic agents for malignant glioma: a case study with high-dose tamoxifen. J. Neuro-Oncol., 35, 39-45 (1997).
6. COULDWELL, W.T., WEISS, M.H., DEGIORGIO, C.M., WEINER, L.P., HINTON, D.R., EHRESMANN, G.R., CONTI, P.S. and APUZZO, M.L.J., Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery, 32, 485-490 (1993).
7. COULDWELL, W.T., WEISS, M.H., LAW, R.E. and HINTON, D.R., Paradoxical elevation of Ki-67 labeling with protein-kinase inhibition in malignant gliomas. J. Neurosurg., 82, 461-468 (1995).
8. GELMAN, E.P., Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol., 24 (Suppl. 1), S1-65-S1-70 (1997).
9. GIESE, A., HAGEL, C., KIM, E.L., ZAPF, S., DJAWAHERI, J., BERENS, M.E. and WESTPHAL, M., Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-Oncology, 1, 3-13 (1999).
10. GIESE, A., LOO, M.A., TRAN, N., HASKETT, D., COONS, S.W. and BERENS, M.E., Dichotomy of astrocytoma migration and proliferation. Int. J. Cancer, 67, 275-282 (1996).
11. GIESE, A., RIEF, M.D., LOO, M.A. and BERENS, M.E., Determinants of human astrocytoma migration. Cancer Res., 54, 3897-3904 (1994).
12. HOTTA, T., TANIMURA, H., YAMAUE, H., IWAHASHI, M., TANI, M., TSUNODA, T., TAMAI, M., NOGUCHI, K., MIZOBATA, S., ARII, K. and TERASAWA, H., Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J. surg. Res., 66, 31-35 (1996).
13. JANIK, P., SZANIAWSKA, B., MILOSZEWSLA, J., PIETRUSZEWSKA, E. and KOWALCZYK, D., The role of protein-kinase C in migration of rat glioma cells from spheroid cultures. Cancer Lett., 63, 167-170 (1992).
14. JOHNSTON, S.R.D., HAYNES, B.P. and SMITH, I.E., Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 342, 1521-1522 (1993).
15. KACZMAREK, E., ZAPF, S., BOUTERFA, H., TONN, J.C., WESTPHAL, M. and GIESE, A., Dissecting glioma invasion: interrelation of adhesion, migration, and intercellular contacts determine the invasive phenotype. Int. J. dev. Neurosci., 17, 625-641 (2000).
16. LUNARDI, P., FARAH, J.O., MASTRONARDI, F., PUZZILLI, F. and LO BIANCO, F.M., Intravenous administration of high doses of carboplatin in multimodal treatment of high-grade gliomas: a phase-II study. Acta neurochir. (Wien), 138, 215-220 (1996).
17. LUPU, R., CARDILLO, M., CHO, C., HARRIS, L., HIJAZI, M., PEREZ, C., ROSENBERG, K., YANG, D. and TANG, C., The significance of heregulin in breast-cancer tumor progression and drug resistance. Breast Cancer Res. Treat., 38, 57-66 (1996).
18. LYKKESFELDT, A.E., Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta oncol., 35 (Suppl. 5), 9-14 (1996).
19. MASTRONARDI, L., PUZILLI, F., COULDWELL, W.T., FARAH, J.O. and LUNARDI, P., Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J. Neuro-Oncol., 38, 59-68 (1998).
20. MCCLAY, E.F., JONES, J.A., WINSKI, P.J., ALBRIGHT, K.D., CHRISTEN, R.D. and HOWELL, S.B., Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res., 56, 3993-3997 (1996).
21. MCCOTTER, D., VAN DEN BERG, H.W., BOYLAN, M. and MCKIBBEN, B., Changes in insulin-like-growth-faclor-1-receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast-cancer cells in vitro. Cancer Lett., 99, 239-245 (1996).
22. NEWBY, J.C., JOHNSTON, S.R.D., SMITH, I.E. and DOWSETT, M., Expression of epidermal-growth-factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res., 3, 1643-1651 (1997).
23. PARISOT, J.P., HU, X.F., DELUISE, M. and ZALCBERG, J.R., Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast-cancer cell line. Brit. J. Cancer, 79, 693-700 (1999).
24. PEYRAT, J.-P., BONNETERRE, J., LUBIN, R., VANLEMMENS, L., FOURNIER, J. and SOUSSI, T., Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet, 345, 621-622 (1995).
25. PUCHNER, M.J.A., HERRMANN, H.D. and CRISTANTE, L., Glioblastoma treatment with surgery, tamoxifen, carboplatin and radiotherapy, In: 11th European Congress of Neurosurgery - European Association of Neurological Societies (EANS), pp. 289-294, Monduzzi, Bologna (1999).
26. RIORDAN, J.R., DEUCHARS, K., KARTNER, N., ALON, N., TRENT, J. and LING, V., Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature (Lond.), 316, 817-819 (1985).
27. VERTOSICK, F.T., JR., SELKER, R.G., RANDALL, M.S., KRISTOFIK, M.P. and REHN, T., A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J. Neuro-Oncol., 19, 97-103 (1994).
28. WELLER, M., TREPEL, M., GRIMMEL, C., SCHABET, M., BREMEN, D., KRAJEWSKI, S. and REED, J.C., Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53, Neurol. Res., 19, 459-470 (1997).
29. ZHANG, W., HINTON, D.R., SURNOCK, A.A. and COULDWELL, W.T., Malignant-glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin, corroborating clinical response to in vitro: case report. Neurosurgery, 38, 587-591 (1996).
30. ZHANG, W., LAW, R.E., HINTON, D.R. and COULDWELL, W.T., Inhibition of human malignant-glioma cell motility and invasion in vitro by hypericin, a potent protein-kinase-C inhibitor. Cancer Lett., 120, 31-38 (1997).